Preclinical studies indicate that PRMT1 inhibitors, when used in conjunction with platinum‐based drugs, exhibit a synergistic effect in inhibiting tumor growth [218] or the HIF1α/P300 interaction inhibitor menadione [68]. Here, PRMT1 is linked to neoplasm.